Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

ClinicalTrials.gov ID: NCT05376150

Public ClinicalTrials.gov record NCT05376150. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 27, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Proof-of-Concept, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 in Major Depressive Disorder

Study identification

NCT ID
NCT05376150
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Enrollment
168 participants

Conditions and interventions

Interventions

  • XEN1101 10 mg Drug
  • XEN1101 20 mg Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 18, 2022
Primary completion
Sep 17, 2023
Completion
Oct 15, 2023
Last update posted
Sep 18, 2024

2022 – 2023

United States locations

U.S. sites
20
U.S. states
9
U.S. cities
18
Facility City State ZIP Site status
Advanced Research Center Anaheim California 92805
Sunwise Clinical Research, LLC Lafayette California 94549
California Neuropsychopharmacology Clinical Research Institute Pico Rivera California 90660
Artemis Institute for Clinical Research Riverside California 92503
Artemis Institute for Clinical Research San Diego California 92103
Meridian International Research Miami Florida 33014
Global Medical Institutes (GMI) Miami Florida 33125
CCM Clinical Reseach Group, LLC Miami Florida 33133
i-Research, Atlanta Decatur Georgia 30030
Psych Atlanta, PC Marietta Georgia 30060
iResearch Savannah Georgia 31405
Revive Research Institute, Inc. Elgin Illinois 60123
Altea Research Las Vegas Nevada 89102
Hassman Research Institute Marlton New Jersey 08009
Bio Behavioral Health Toms River New Jersey 08755
Neurobehavioral Research, Inc. (NBR) Cedarhurst New York 11516
Manhattan Behavioral Medicine, PLLC New York New York 10036
Richard M Weisler and Association Raleigh North Carolina 27609
FutureSearch Trials of Dallas, LP Dallas Texas 75231
AIM Trials Plano Texas 75093

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05376150, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 18, 2024 · Synced Jun 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05376150 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →